Title: Evaluation of Circulating Cell-Free DNA in Cholestatic Liver Disease Using Liver-
Specific Methylation Markers
Version: 0 Date: 17 Feb 2021
Reviewer's report:
In this study, Punia et al. seek the potential of circulating free DNAs as a biomarker for PSC
and PBC. Data look solid to support the authors claims and I do not have any major comments
or criticisms for this manuscript. In Discussion, the authors mention that individual variability
is huge in the data, which could be a problem in this technique. Since the authors mention the
potential of cfDNA as a novel biomarker for PBC and PSC, it would be interesting data if the
authors perform ROC curve analysis and show AUC. It may not be beautiful but useful to show
the difficulties of the current study.
Title: Evaluation of Circulating Cell-Free DNA in Cholestatic Liver Disease Using Liver-
Specific Methylation Markers
Version: 0 Date: 17 Feb 2021
Reviewer's report:
In this study, Punia et al. seek the potential of circulating free DNAs as a biomarker for PSC
and PBC. Data look solid to support the authors claims and I do not have any major comments
or criticisms for this manuscript. In Discussion, the authors mention that individual variability
is huge in the data, which could be a problem in this technique. Since the authors mention the
potential of cfDNA as a novel biomarker for PBC and PSC, it would be interesting data if the
authors perform ROC curve analysis and show AUC. It may not be beautiful but useful to show
the difficulties of the current study.
Please review this paper.
user
Title: Evaluation of Circulating Cell-Free DNA in Cholestatic Liver Disease Using Liver-
Specific Methylation Markers
Version: 0 Date: 17 Feb 2021
Reviewer's report:
In this study, Punia et al. seek the potential of circulating free DNAs as a biomarker for PSC
and PBC. Data look solid to support the authors claims and I do not have any major comments
or criticisms for this manuscript. In Discussion, the authors mention that individual variability
is huge in the data, which could be a problem in this technique. Since the authors mention the
potential of cfDNA as a novel biomarker for PBC and PSC, it would be interesting data if the
authors perform ROC curve analysis and show AUC. It may not be beautiful but useful to show
the difficulties of the current study.
assistant